NRPa-308

Overview

NRPa-308 is a potent and orally active Neuropilin-1 (NRP-1) antagonist with an IC 50 of 42 μM for inhibiting VEGF-A 165 binding to NRP-1 . NRPa-308 blocks the specific interaction between VEGF-A 165 and NRP-1. NRPa-308 effectively suppresses angiogenesis in vitro and in vivo and reduces the viability of a broad spectrum of human solid and haematological cancer cells. NRPa-308 inhibits tumor growth and prolongs median survival in a human breast cancer xenograft mouse model. NRPa-308 can be used for the research of multiple human malignancies including solid tumors and hematological cancers.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Complement System | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-182700
• CAS No.: 717863-53-1
• Molecular Formula: C23H24N2O4S
• Molecular Weight: 424.51
• Purity: 98.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source